Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Myristica fragrans

ABSTRACT: Myristica fragrans overview

PROVIDER: PRJNA806314 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR16832004_1.fastq.gz	Fastqsanger.gz
	SRR16832004_2.fastq.gz	Fastqsanger.gz

Items per page:

1 - 2 of 2

Similar Datasets

Myristica fragrans

Project description:Myristica fragrans Genome sequencing and assembly

| PRJNA778329 | ENA

Myricone C, a novel neolignan from Myristica fragrans, induces ER stress-mediated apoptosis in gastric and colorectal cancer via ROCK inhibition

Project description:Gastric and colorectal cancers remain leading causes of cancer-related mortality worldwide, highlighting the need for novel therapeutic strategies. Here, we report the potent anticancer activity of myricone C (MyrC), a novel neolignan and diarylnonanoid derivative isolated from Myristica fragrans, as a potent anticancer agent against these malignancies in vitro and in vivo. MyrC exhibited significant cytotoxicity in human gastric and colorectal cancer cell lines (IC50 values: 2.1–9.8 µM). Mechanistic studies revealed that MyrC induces G1 phase cell cycle arrest (gastric cells), increases the apoptosis-associated sub-G1 fraction (colorectal cells), and triggers apoptosis. Comprehensive transcriptomic analysis (RNA-seq, GSEA), validated by targeted qPCR and Western blotting, demonstrated that MyrC robustly induces endoplasmic reticulum (ER) stress, activates the unfolded protein response (UPR) primarily via the PERK-eIF2α-ATF4-CHOP axis, and upregulates downstream pro-apoptotic signaling. Furthermore, in silico docking predicted, and in vitro kinase assays confirmed, that MyrC directly binds and potently inhibits ROCK1 and ROCK2 kinases (IC50 values: 206–247 nM), which are implicated in cancer progression and potentially influence ER stress responses. Importantly, MyrC significantly suppressed tumor growth in a gastric cancer xenograft model in vivo without overt toxicity. These findings establish MyrC as a promising therapeutic lead candidate for gastric and colorectal cancer.

2025-05-05 | GSE296060 | GEO

Myristica yunnanensis

Project description:Myristica yunnanensis overview

| PRJNA827908 | ENA

Anneslea fragrans

Project description:Anneslea fragrans overview

| PRJNA488845 | ENA

Dracaena fragrans

Project description:Dracaena fragrans overview

| PRJNA717869 | ENA

Cephaloascus fragrans

Project description:Cephaloascus fragrans overview